Seeking Alpha News (Wed, 5-Aug 7:47 AM ET)
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
Globe Newswire (Wed, 5-Aug 7:00 AM ET)
Piper Sandler Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
TipRanks (Tue, 4-Aug 9:28 AM ET)
NewAmsterdam Pharma to Host Investor Day on August 5, 2026
Globe Newswire (Wed, 29-Jul 8:00 AM ET)
Globe Newswire (Fri, 24-Jul 8:00 AM ET)
Attovia Therapeutics Appoints John W. Smither to Board of Directors
Globe Newswire (Wed, 15-Jul 8:30 AM ET)
Market Chameleon (Mon, 6-Jul 4:36 AM ET)
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Thu, 2-Jul 4:01 PM ET)
Globe Newswire (Wed, 1-Jul 8:00 AM ET)
Globe Newswire (Wed, 3-Jun 8:00 AM ET)
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Newamsterdam Pharma Company N.V. - trades on the NASDAQ stock market under the symbol NAMS.
As of August 5, 2026, NAMS stock price declined to $27.19 with 332,228 million shares trading.
NAMS has a beta of 1.24, meaning it tends to be more sensitive to market movements. NAMS has a correlation of 0.05 to the broad based SPY ETF.
NAMS has a market cap of $3.18 billion. This is considered a Mid Cap stock.
Last quarter Newamsterdam Pharma Company N.V. - reported $3 million in Revenue and -$.40 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.03.
In the last 3 years, NAMS traded as high as $42.21 and as low as $5.63.
The top ETF exchange traded funds that NAMS belongs to (by Net Assets): CGMM, IBB, VHT, SBIO, ESML.
NAMS has outperformed the market in the last year with a return of +25.5%, while the SPY ETF gained +24.1%. However, in the most recent history, NAMS shares have underperformed the stock market with its stock returning -8.9% in the last 3 month period and -15.9% for the last 2 week period, while SPY has returned +8.3% and +3.7%, respectively.
NAMS support price is $26.44 and resistance is $28.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NAMS shares will trade within this expected range on the day.
